Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses PFE in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PFE in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Albert Bourla | $1,800,000 | $0 | $9,442,705 | $8,998,141 | $5,400,000 | $4,014 | $1,940,441 | $27,585,301 |
| Chairman and Chief Executive Officer | ||||||||
| Chris Boshoff | 1,400,000 | 0 | 1,808,655 | 2,999,378 | 3,150,000 | 0 | 648,006 | 10,006,039 |
| Chief Scientific Officer and President, Research & Development | ||||||||
| David Denton | 1,388,964 | 0 | 2,367,893 | 2,499,485 | 2,800,000 | 0 | 613,840 | 9,670,182 |
| Chief Financial Officer, Executive Vice President | ||||||||
| Aamir Malik | 1,386,817 | 0 | 2,281,630 | 2,249,535 | 2,900,000 | 0 | 611,245 | 9,429,227 |
| Chief U.S. Commercial Officer, Executive Vice President | ||||||||
| Douglas Lankler | 1,411,787 | 0 | 1,976,390 | 2,249,535 | 2,675,000 | 257,976 | 535,588 | 9,106,276 |
| Chief Legal Officer, Executive Vice President | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Albert Bourla | $27,585,301 | $24,648,727 | $21,562,064 | +2,936,574 |
| Chris Boshoff | 10,006,039 | 7,853,984 | — | +2,152,055 |
| David Denton | 9,670,182 | 8,124,542 | 5,279,536 | +1,545,640 |
| Aamir Malik | 9,429,227 | 8,294,270 | 5,420,734 | +1,134,957 |
| Douglas Lankler | 9,106,276 | 6,814,115 | 5,477,798 | +2,292,161 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Albert Bourla | Director | 2026-03-13 | A | 1,630 | $27 | $43,325 | Derivative, Class A Common | Form 4 ↗ |
| James C. Smith | Director | 2026-03-27 | A | 1,664.2 | 27 | 45,000 | Derivative, Class A Common | Form 4 ↗ |
| Cyrus Taraporevala | Director | 2026-03-27 | A | 1,386.83 | 27 | 37,500 | Derivative, Class A Common | Form 4 ↗ |
| Joseph J. Echevarria | Director | 2026-03-27 | A | 1,710.43 | 27 | 46,250 | Derivative, Class A Common | Form 4 ↗ |
| Mortimer J. Buckley | Director | 2026-03-27 | A | 1,386.83 | 27 | 37,500 | Derivative, Class A Common | Form 4 ↗ |
| James Quincey | Director | 2026-03-27 | A | 1,433.06 | 27 | 38,750 | Derivative, Class A Common | Form 4 ↗ |
| Shantanu Narayen | Director | 2026-03-27 | A | 1,849.11 | 27 | 50,000 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-03-31 | — | 21 | — | ~590 | 1 insider, 1 accrual row | ||
| Albert Bourla | Director | 2026-04-14 | A | 911 | 27 | 24,697 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-04-15 | — | 22 | — | ~598 | 1 insider, 1 accrual row | ||
| Susan Desmond-Hellmann | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| Joseph J. Echevarria | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| James C. Smith | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| Scott Gottlieb | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| Mortimer J. Buckley | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| NORA JOHNSON SUZANNE M | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| Ronald E. Blaylock | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| Dan R. Littman | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| Cyrus Taraporevala | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| James Quincey | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| Shantanu Narayen | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-04-30 | — | 22 | — | ~587 | 1 insider, 1 accrual row | ||
| Dividend-equivalent accruals | 2026-05-15 | — | 24 | — | ~608 | 1 insider, 1 accrual row | ||
| Dividend-equivalent accruals | 2026-05-29 | — | 23 | — | ~602 | 1 insider, 1 accrual row | ||
| Jennifer B. Damico | SVP & Controller | 2026-06-09 | D | 2,000 | 26 | 51,400 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-15 | — | 23 | — | ~598 | 1 insider, 1 accrual row | ||
| Cyrus Taraporevala | Director | 2026-06-26 | A | 1,543.85 | 24 | 37,500 | Derivative, Class A Common | Form 4 ↗ |
| James Quincey | Director | 2026-06-26 | A | 1,595.31 | 24 | 38,750 | Derivative, Class A Common | Form 4 ↗ |
| Mortimer J. Buckley | Director | 2026-06-26 | A | 1,543.85 | 24 | 37,500 | Derivative, Class A Common | Form 4 ↗ |
| Shantanu Narayen | Director | 2026-06-26 | A | 2,058.46 | 24 | 50,000 | Derivative, Class A Common | Form 4 ↗ |
| James C. Smith | Director | 2026-06-26 | A | 1,852.61 | 24 | 45,000 | Derivative, Class A Common | Form 4 ↗ |
| Joseph J. Echevarria | Director | 2026-06-26 | A | 1,904.08 | 24 | 46,250 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-30 | — | 25 | — | ~602 | 1 insider, 1 accrual row | ||
| Dividend-equivalent accruals | 2026-07-09 | — | 84 | — | ~2,037 | 1 insider, 1 accrual row | ||
| Dividend-equivalent accruals | 2026-07-15 | — | 24 | — | ~596 | 1 insider, 1 accrual row | ||
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Albert Bourla | Director | 2026-03-13 | A | 1,630 | $27 | $43,325 | Derivative, Class A Common | Form 4 ↗ |
| James C. Smith | Director | 2026-03-27 | A | 1,664.2 | 27 | 45,000 | Derivative, Class A Common | Form 4 ↗ |
| Cyrus Taraporevala | Director | 2026-03-27 | A | 1,386.83 | 27 | 37,500 | Derivative, Class A Common | Form 4 ↗ |
| Joseph J. Echevarria | Director | 2026-03-27 | A | 1,710.43 | 27 | 46,250 | Derivative, Class A Common | Form 4 ↗ |
| Mortimer J. Buckley | Director | 2026-03-27 | A | 1,386.83 | 27 | 37,500 | Derivative, Class A Common | Form 4 ↗ |
| James Quincey | Director | 2026-03-27 | A | 1,433.06 | 27 | 38,750 | Derivative, Class A Common | Form 4 ↗ |
| Shantanu Narayen | Director | 2026-03-27 | A | 1,849.11 | 27 | 50,000 | Derivative, Class A Common | Form 4 ↗ |
| Albert Bourla | Director | 2026-03-31 | A | 21 | 28 | 590 | Derivative, Class A Common | Form 4 ↗ |
| Albert Bourla | Director | 2026-04-14 | A | 911 | 27 | 24,697 | Derivative, Class A Common | Form 4 ↗ |
| Albert Bourla | Director | 2026-04-15 | A | 22 | 27 | 598 | Derivative, Class A Common | Form 4 ↗ |
| Susan Desmond-Hellmann | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| Joseph J. Echevarria | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| James C. Smith | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| Scott Gottlieb | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| Mortimer J. Buckley | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| NORA JOHNSON SUZANNE M | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| Ronald E. Blaylock | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| Dan R. Littman | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| Cyrus Taraporevala | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| James Quincey | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| Shantanu Narayen | Director | 2026-04-23 | A | 7,686.54 | 27 | 205,000 | Derivative, Class A Common | Form 4 ↗ |
| Albert Bourla | Director | 2026-04-30 | A | 22 | 27 | 587 | Derivative, Class A Common | Form 4 ↗ |
| Albert Bourla | Director | 2026-05-15 | A | 24 | 25 | 608 | Derivative, Class A Common | Form 4 ↗ |
| Albert Bourla | Director | 2026-05-29 | A | 23 | 26 | 602 | Derivative, Class A Common | Form 4 ↗ |
| Jennifer B. Damico | SVP & Controller | 2026-06-09 | D | 2,000 | 26 | 51,400 | Common | Form 4 ↗ |
| Albert Bourla | Director | 2026-06-15 | A | 23 | 26 | 598 | Derivative, Class A Common | Form 4 ↗ |
| Cyrus Taraporevala | Director | 2026-06-26 | A | 1,543.85 | 24 | 37,500 | Derivative, Class A Common | Form 4 ↗ |
| James Quincey | Director | 2026-06-26 | A | 1,595.31 | 24 | 38,750 | Derivative, Class A Common | Form 4 ↗ |
| Mortimer J. Buckley | Director | 2026-06-26 | A | 1,543.85 | 24 | 37,500 | Derivative, Class A Common | Form 4 ↗ |
| Shantanu Narayen | Director | 2026-06-26 | A | 2,058.46 | 24 | 50,000 | Derivative, Class A Common | Form 4 ↗ |
| James C. Smith | Director | 2026-06-26 | A | 1,852.61 | 24 | 45,000 | Derivative, Class A Common | Form 4 ↗ |
| Joseph J. Echevarria | Director | 2026-06-26 | A | 1,904.08 | 24 | 46,250 | Derivative, Class A Common | Form 4 ↗ |
| Albert Bourla | Director | 2026-06-30 | A | 25 | 24 | 602 | Derivative, Class A Common | Form 4 ↗ |
| Albert Bourla | Director | 2026-07-09 | A | 84 | 24 | 2,037 | Derivative, Class A Common | Form 4 ↗ |
| Albert Bourla | Director | 2026-07-15 | A | 24 | 25 | 596 | Derivative, Class A Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Douglas Lankler | PSU | 2025-03-04 | — | 76,753 | 76,753 | 153,506 | $1,976,390 |
| Albert Bourla | OPTION | 2025-03-04 | — | — | 1,487,296 | — | 8,998,141 |
| Albert Bourla | PSU | 2025-03-04 | — | 366,707 | 366,707 | 733,414 | 9,442,705 |
| David Denton | PSU | 2025-03-04 | — | 91,957 | 91,957 | 183,914 | 2,367,893 |
| Chris Boshoff | PSU | 2025-03-04 | — | 66,726 | 66,726 | 133,452 | 1,718,195 |
| David Denton | OPTION | 2025-03-04 | — | — | 413,138 | — | 2,499,485 |
| Chris Boshoff | PSU | 2025-03-04 | — | 3,513 | 3,513 | 7,026 | 90,460 |
| Chris Boshoff | OPTION | 2025-03-04 | — | — | 495,765 | — | 2,999,378 |
| Aamir Malik | OPTION | 2025-03-04 | — | — | 371,824 | — | 2,249,535 |
| Douglas Lankler | OPTION | 2025-03-04 | — | — | 371,824 | — | 2,249,535 |
| Aamir Malik | PSU | 2025-03-04 | — | 88,607 | 88,607 | 177,214 | 2,281,630 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Douglas Lankler | $0 | $1,976,390 | $2,249,535 | 46.8% |
| Albert Bourla | 0 | 9,442,705 | 8,998,141 | 51.2% |
| David Denton | 0 | 2,367,893 | 2,499,485 | 48.6% |
| Chris Boshoff | 0 | 1,808,655 | 2,999,378 | 37.6% |
| Aamir Malik | 0 | 2,281,630 | 2,249,535 | 50.4% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Chris Boshoff | PSU | 83,674 | — | $2,083,483 |
| David Denton | PSU | 52,693 | — | 1,312,056 |
| Douglas Lankler | Option | 55,758 | 45.96 | — |
| David Denton | PSU | 42,421 | — | 1,056,283 |
| Chris Boshoff | Option | 495,765 | 25.75 | — |
| Aamir Malik | PSU | 83,674 | — | 2,083,483 |
| David Denton | Option | 142,400 | 26.89 | — |
| David Denton | Option | 103,320 | 42.3 | — |
| Chris Boshoff | PSU | 116,505 | — | 2,900,975 |
| Albert Bourla | Option | 412,081 | 45.96 | — |
| Albert Bourla | Option | 362,427 | 45.96 | — |
| Albert Bourla | Option | 413,280 | 42.3 | — |
| Albert Bourla | Option | 569,600 | 26.89 | — |
| Albert Bourla | PSU | 334,697 | — | 8,333,955 |
| Douglas Lankler | Option | 371,824 | 25.75 | — |
| Douglas Lankler | PSU | 65,080 | — | 1,620,492 |
| Douglas Lankler | PSU | 40,984 | — | 1,020,502 |
| Aamir Malik | Option | 103,320 | 42.3 | — |
| Douglas Lankler | Option | 106,195 | 33.82 | — |
| David Denton | Option | 89,920 | 42.3 | — |
| Aamir Malik | Option | 161,160 | 26.89 | — |
| David Denton | PSU | 97,087 | — | 2,417,466 |
| David Denton | Option | 80,703 | 53.04 | — |
| Aamir Malik | PSU | 52,693 | — | 1,312,056 |
| Chris Boshoff | Option | 142,400 | 26.89 | — |
| Douglas Lankler | Option | 80,360 | 42.3 | — |
| Chris Boshoff | PSU | 34,992 | — | 871,301 |
| Chris Boshoff | PSU | 10,539 | — | 262,421 |
| Albert Bourla | Option | 499,353 | 31.31 | — |
| David Denton | Option | 70,313 | 53.04 | — |
| Aamir Malik | Option | 74,344 | 45.96 | — |
| Douglas Lankler | Option | 80,058 | 38.71 | — |
| Douglas Lankler | Option | 134,441 | 31.31 | — |
| Douglas Lankler | Option | 125,347 | 26.89 | — |
| Albert Bourla | PSU | 349,515 | — | 8,702,924 |
| Albert Bourla | PSU | 210,773 | — | 5,248,248 |
| Albert Bourla | PSU | 205,133 | — | 5,107,812 |
| Aamir Malik | PSU | 87,379 | — | 2,175,737 |
| Aamir Malik | PSU | 42,079 | — | 1,047,767 |
| Chris Boshoff | PSU | 39,529 | — | 984,272 |
| Douglas Lankler | PSU | 36,819 | — | 916,793 |
| Chris Boshoff | Option | 17,984 | 42.3 | — |
| Aamir Malik | Option | 84,529 | 45.96 | — |
| Aamir Malik | Option | 89,920 | 42.3 | — |
| Aamir Malik | Option | 142,400 | 26.89 | — |
| Douglas Lankler | Option | 9,294 | 46.94 | — |
| Aamir Malik | Option | 371,824 | 25.75 | — |
| Douglas Lankler | Option | 69,938 | 42.3 | — |
| Douglas Lankler | Option | 110,756 | 26.89 | — |
| Albert Bourla | Option | 320,231 | 38.71 | — |
| Albert Bourla | Option | 359,681 | 42.3 | — |
| Albert Bourla | Option | 644,640 | 26.89 | — |
| Albert Bourla | Option | 1,487,296 | 25.75 | — |
| Chris Boshoff | Option | 12,009 | 38.71 | — |
| Chris Boshoff | Option | 21,127 | 31.31 | — |
| Chris Boshoff | Option | 10,222 | 45.96 | — |
| Douglas Lankler | Option | 122,907 | 33.82 | — |
| Chris Boshoff | PSU | 2,073 | — | 51,618 |
| Chris Boshoff | Option | 16,688 | 33.82 | — |
| David Denton | Option | 161,160 | 26.89 | — |
| Chris Boshoff | Option | 161,160 | 26.89 | — |
| Douglas Lankler | PSU | 87,379 | — | 2,175,737 |
| David Denton | PSU | 83,674 | — | 2,083,483 |
| Albert Bourla | Option | 491,626 | 33.82 | — |
| Albert Bourla | Option | 424,782 | 33.82 | — |
| David Denton | Option | 413,138 | 25.75 | — |
| Douglas Lankler | Option | 63,397 | 45.96 | — |
| Douglas Lankler | Option | 10,566 | 46.94 | — |
Our executive compensation program is designed to attract and retain highly qualified executives and incentivize them to create value and advance the interests of our shareholders. Consistent with Pfizer's compensation philosophy, the program aligns pay with performance and supports long term value creation.
| CEO STI target (% of salary) | 200% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Meridian Compensation Partners, LLC |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-04-23 | 3,099,249,442 | 423,935,881 | 33,443,287 | 87.97% | Passed |
| 2025 | 2025-04-24 | 1,947,064,397 | 1,612,203,678 | 21,901,539 | 54.7% | Passed |
| 2024 | 2024-04-25 | 3,360,637,251 | 315,293,726 | 26,256,736 | 91.42% | Passed |
| 2023 | 2023-04-27 | 3,579,314,991 | 278,786,983 | 27,817,386 | 92.77% | Passed |
| 2022 | 2022-04-28 | 3,509,011,827 | 275,230,428 | 25,057,788 | 92.73% | Passed |
| 2021 | 2021-04-22 | 3,355,194,651 | 258,664,414 | 31,349,637 | 92.84% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-04-23 | 87.97%a |
| 2025 | 2025-04-24 | 54.7%b |
| 2024 | 2024-04-25 | 91.42%c |
a. Approved under the standard stated in the filing — “Advisory Approval of Executive Compensation Majority of Votes Cast No”.
b. Approved under the standard stated in the filing — “Abstentions/Broker Non-Votes: If you abstain from voting or there is a broker non-vote on any matter, your abstention or broker non-vote will not affect the outcome of such vote, because abstentions and broker non-votes are not considered to be votes cast under our By-laws.”.
c. Approved under the standard stated in the filing — “Abstentions/Broker Non-Votes: If you abstain from voting or there is a broker non-vote on any matter, your abstention or broker non-vote will not affect the outcome of such vote, because abstentions and broker non-votes are not considered to be votes cast under our By-laws.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 277 : 1 |
|---|---|
| CEO total compensation | $27,585,301 |
| Median employee compensation | $99,631 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Suzanne Nora JohnsonIndependent · Audit (Chair) · Regulatory and Compliance | $185,000 | $205,000 | $0 | — | $20,000 | $410,000 |
| Shantanu NarayenIndependent · Lead Independent Director | 205,000 | 205,000 | 0 | — | — | 410,000 |
| Joseph J. EchevarriaIndependent · Audit · Governance (Chair) | 185,000 | 205,000 | 0 | — | 10,372 | 400,372 |
| Scott GottliebIndependent · Regulatory and Compliance (Chair) · Science and Technology | 185,000 | 205,000 | 0 | — | 3,500 | 393,500 |
| James C. SmithIndependent · Audit · Compensation (Chair) | 185,000 | 205,000 | 0 | — | — | 390,000 |
| Susan Desmond-HellmannIndependent · Governance · Science and Technology (Chair) | 175,522 | 205,000 | 0 | — | — | 380,522 |
| Cyrus TaraporevalaIndependent · Audit · Compensation | 155,000 | 205,000 | 0 | — | 20,000 | 380,000 |
| Dan R. LittmanIndependent · Governance · Regulatory and Compliance · Science and Technology | 155,000 | 205,000 | 0 | — | 20,000 | 380,000 |
| James QuinceyIndependent · Compensation | 155,000 | 205,000 | 0 | — | 20,000 | 380,000 |
| Susan HockfieldIndependent · Regulatory and Compliance · Science and Technology · Not standing for re-election | 155,000 | 205,000 | 0 | — | 12,000 | 372,000 |
| Mortimer J. BuckleyIndependent · Audit · Governance | 155,000 | 205,000 | 0 | — | — | 360,000 |
| Ronald E. BlaylockIndependent · Audit · Compensation | 155,000 | 205,000 | 0 | — | — | 360,000 |
| Helen H. HobbsIndependent · Audit · Compensation · Departed during FY | 58,448 | — | 0 | — | — | 58,448 |
| Albert BourlaEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $155,000 |
|---|---|
| Annual equity retainer | $205,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | 5x annual cash retainer ($775,000) |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $2,108,970 |
| Equity awards (grant-date value) | $2,460,000 |
| All other compensation | $105,872 |
| Total cost of the board | $4,674,842 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Pfizer Inc names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Pfizer Inc.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific Inc. | 2025 | Marc Casper | $1,785,534 | $65,730,211 | $7,951,377 | $3,742,123 | $79,923,350 |
| 2 | International Business Machines Corporation | 2025 | Arvind Krishna | 1,500,000 | 23,988,586 | 6,606,312 | 5,250,000 | 37,989,685 |
| 3 | Eli Lilly and Company | 2025 | David Ricks | 1,700,000 | 23,325,000 | 0 | 6,485,500 | 36,698,337 |
| 4 | Comcast Corporation | 2025 | Brian Roberts | 2,600,962 | 23,473,076 | 0 | 8,583,175 | 35,148,413 |
| 5 | Verizon Communications Inc. | 2025 | Daniel Schulman | 375,000 | 32,774,795 | 0 | 937,500 | 34,311,016 |
| 6 | Johnson & Johnson | 2025 | Joaquin Duato | 1,600,000 | 15,028,948 | 5,927,995 | 4,298,700 | 32,758,111 |
| 7 | AbbVie Inc. | 2025 | Robert Michael | 1,700,000 | 13,268,456 | 3,199,154 | 5,200,000 | 32,530,984 |
| 8 | The Coca-Cola Company | 2025 | James Quincey | 1,675,000 | 12,516,109 | 10,352,255 | 5,025,000 | 31,208,165 |
| 9 | Gilead Sciences, Inc. | 2025 | Daniel O'Day | 1,795,192 | 15,238,402 | 4,500,060 | 4,848,120 | 28,437,198 |
| 10 | Pfizer Inc | 2025 | Albert Bourla | 1,800,000 | 9,442,705 | 8,998,141 | 5,400,000 | 27,585,301 |
| 11 | Chevron Corporation | 2025 | Michael Wirth | 1,900,000 | 13,524,995 | 4,376,640 | 3,562,500 | 26,828,240 |
| 12 | RTX Corporation | 2025 | Christopher Calio | 1,525,000 | 10,875,391 | 6,753,909 | 0 | 24,846,826 |
| 13 | Amgen Inc. | 2025 | Robert Bradway | 1,925,409 | 12,599,589 | 5,399,996 | 3,907,000 | 24,693,120 |
| 14 | Mondelez International, Inc. | 2025 | Dirk Van de Put | 1,624,615 | 14,530,359 | 4,401,555 | 3,234,000 | 24,516,114 |
| 15 | Abbott Laboratories | 2025 | Robert Ford | 1,500,000 | 8,787,378 | 8,788,430 | 1,968,750 | 24,198,660 |
| 16 | PepsiCo, Inc. | 2025 | Ramon Laguarta | 1,804,615 | 11,550,008 | 0 | 5,771,000 | 23,903,545 |
| 17 | Danaher Corporation | 2025 | Rainer Blair | 1,400,000 | 9,292,370 | 8,386,657 | 4,194,400 | 23,795,280 |
| 18 | Lockheed Martin Corporation | 2025 | James Taiclet | 1,751,000 | 13,667,645 | 0 | 5,496,300 | 23,453,308 |
| 19 | ConocoPhillips | 2025 | Ryan Lance | 1,800,000 | 16,543,434 | 0 | 4,590,000 | 23,450,085 |
| 20 | Medtronic plc | 2026 | Geoffrey Martha | 1,399,039 | 13,672,200 | 5,175,559 | 2,307,200 | 22,940,252 |
| 21 | United Parcel Service, Inc. | 2025 | Carol Tomé | 1,509,713 | 17,550,546 | 1,358,754 | 2,264,569 | 22,878,788 |
| 22 | The Procter & Gamble Company | 2025 | Jon Moeller | 1,637,500 | 11,519,645 | 6,562,515 | 0 | 21,909,816 |
| 23 | Bristol-Myers Squibb Company | 2025 | Christopher Boerner | 1,586,346 | 16,061,399 | 0 | 3,754,684 | 21,879,919 |
| 24 | 3M Company | 2025 | William Brown | 1,800,000 | 7,753,852 | 7,001,242 | 3,745,322 | 21,005,009 |
| 25 | Merck & Co., Inc. | 2025 | Robert Davis | 1,645,302 | 12,102,838 | 3,380,004 | 2,326,500 | 20,797,845 |
| 26 | Honeywell International Inc. | 2025 | Vimal Kapur | 1,600,000 | 10,866,269 | 3,623,914 | 3,516,800 | 20,381,435 |
| 27 | Caterpillar Inc. | 2025 | Joseph Creed | 1,381,892 | 9,538,484 | 3,101,117 | 2,476,800 | 17,008,077 |
| — | Novartis AG | — | — | — | — | — | — | not in coverage universe |
| — | Sanofi | — | — | — | — | — | — | not in coverage universe |
| — | AstraZeneca PLC | — | — | — | — | — | — | not in coverage universe |
| — | GSK plc | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Pfizer Inc | 150% | PSU 50 · MSU 50 | Yes — relative TSR as compared to the NYSE Arca Pharmaceutical Index (DRG Index or DRG) | Meridian Compensation Partners, LLC |
| 3M Company | 118.9% | PSU 50 · Options 50 | No | FW Cook |
| Abbott Laboratories | 75.0% | Options 50 · PSU 50 | No | Meridian Compensation Partners, LLC |
| AbbVie Inc. | not disclosed | PSU 40 · RSU 40 · Options 20 | Yes — Relative TSR | Semler Brossy |
| Amgen Inc. | 136.0% | PSU 50 · Options 30 · RSU 20 | Yes — relative TSR | Frederic W. Cook & Co., Inc. (FW Cook) |
| AstraZeneca PLC | not disclosed | not disclosed | not disclosed | not disclosed |
| Bristol-Myers Squibb Company | 157.66% | PSU 60 · MSU 40 | Yes — 3-Year Relative TSR CAGR | Farient Advisors LLC |
| Caterpillar Inc. | 118% | PSU 50 · RSU 25 · Options 25 | Yes — relative Total Shareholder Return (rTSR) | Meridian Compensation Partners, LLC |
| Chevron Corporation | 125% | PSU 50 · RSU 25 · Options 25 | Yes — Relative Total Stockholder Return (TSR) | Meridian Compensation Partners, LLC |
| Comcast Corporation | 110% | PSU 100 | Yes — Relative TSR Modifier | Korn Ferry |
| ConocoPhillips | not disclosed | not disclosed | not disclosed | not disclosed |
| Danaher Corporation | not disclosed | Options 50 · RSU 50 | not disclosed | FW Cook |
| Eli Lilly and Company | 218% | PSU 100 | No | FW Cook |
| Gilead Sciences, Inc. | 180% | PSU 50 · Options 25 · RSU 25 | Yes — Relative TSR | FW Cook |
| GSK plc | not disclosed | not disclosed | not disclosed | not disclosed |
| Honeywell International Inc. | 126% | PSU 50 · Options 25 · RSU 25 | Yes — three-year total shareowner return (TSR) relative to the 2025 Compensation Peer Group | not disclosed |
| International Business Machines Corporation | 150% | not disclosed | Yes — Relative Total Shareholder Return (rTSR) | Semler Brossy |
| Johnson & Johnson | not disclosed | not disclosed | not disclosed | Semler Brossy Consulting Group |
| Lockheed Martin Corporation | 114% | PSU 50 · RSU 30 · Cash LTI 20 | Yes — Relative TSR | Meridian Compensation Partners |
| Medtronic plc | 103% | PSU 50 · Options 30 · RSU 20 | No | Semler Brossy |
| Merck & Co., Inc. | 94% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (R-TSR) | FW Cook |
| Mondelez International, Inc. | 91% | PSU 75 · Options 25 | No | not disclosed |
| Novartis AG | not disclosed | not disclosed | not disclosed | not disclosed |
| PepsiCo, Inc. | not disclosed | not disclosed | Yes — Relative TSR Performance | FW Cook |
| RTX Corporation | 164% | PSU 60 · Options 40 | Yes — TSR vs. Core A&D Peers | FW Cook |
| Sanofi | not disclosed | not disclosed | not disclosed | not disclosed |
| The Coca-Cola Company | 150% | PSU 50 · Options 50 | Yes — Relative TSR modifier | Meridian Compensation Partners, LLC |
| The Procter & Gamble Company | 57% | PSU 50 | Yes — Relative TSR Multiplier | Meridian Compensation Partners, LLC |
| Thermo Fisher Scientific Inc. | 99.8% | PSU 50 · Options 50 | Yes — Relative TSR | Pearl Meyer |
| United Parcel Service, Inc. | 75% | PSU 93 · Options 7 | Yes — Relative Total Shareowner Return (RTSR) | FW Cook |
| Verizon Communications Inc. | 100% | PSU 60 · RSU 40 | Yes — relative total shareholder return (TSR) position compared with the companies in the S&P 100 | Meridian Compensation Partners, LLC |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Albert Bourla | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Compensation Tables”. As printed: 27,585,301. Filing ↗machine: t242 · r3 · c12 · span 1506825–1506835 |
| 2 | Section 01, Chris Boshoff | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “SUMMARY COMPENSATION TABLE”. As printed: 10,006,039. Filing ↗machine: t265 · r9 · c16 · span 1650317–1650327 |
| 3 | Section 01, David Denton | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Compensation Tables”. As printed: 9,670,182. Filing ↗machine: t242 · r5 · c12 · span 1509341–1509350 |
| 4 | Section 01, Aamir Malik | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “SUMMARY COMPENSATION TABLE”. As printed: 9,429,227. Filing ↗machine: t265 · r12 · c16 · span 1657931–1657940 |
| 5 | Section 01, Douglas Lankler | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “SUMMARY COMPENSATION TABLE”. As printed: 9,106,276. Filing ↗machine: t265 · r16 · c16 · span 1668923–1668932 |
| 6 | Section 03, Douglas Lankler PSU | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t272 · r18 · c7 · span 1778948–1778954 |
| 7 | Section 03, Albert Bourla OPTION | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t272 · r4 · c13 · span 1743978–1743987 |
| 8 | Section 03, Albert Bourla PSU | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t272 · r5 · c7 · span 1745692–1745699 |
| 9 | Section 03, David Denton PSU | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t272 · r8 · c7 · span 1753648–1753654 |
| 10 | Section 03, Chris Boshoff PSU | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t272 · r11 · c14 · span 1762652–1762661 |
| 11 | Section 03, David Denton OPTION | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t174 · r3 · c1 · span 1082242–1082249 |
| 12 | Section 03, Chris Boshoff PSU | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t272 · r12 · c14 · span 1765485–1765491 |
| 13 | Section 03, Chris Boshoff OPTION | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t272 · r10 · c13 · span 1759816–1759825 |
| 14 | Section 03, Aamir Malik OPTION | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t174 · r5 · c1 · span 1086765–1086772 |
| 15 | Section 03, Douglas Lankler OPTION | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t272 · r17 · c13 · span 1776978–1776987 |
| 16 | Section 03, Aamir Malik PSU | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t272 · r15 · c7 · span 1771127–1771133 |
| 17 | Section 07, pay ratio | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “CEO Pay Ratio”. As printed: 277 : 1. Filing ↗machine: t312 · r3 · c1 · span 2197487–2197494 |
| 18 | Section 08, Suzanne Nora Johnson | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Director Compensation”. As printed: 410,000. Filing ↗machine: t134 · r11 · c7 · span 843142–843149 |
| 19 | Section 08, Shantanu Narayen | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Director Compensation”. As printed: 410,000. Filing ↗machine: t134 · r10 · c7 · span 841483–841490 |
| 20 | Section 08, Joseph J. Echevarria | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Director Compensation”. As printed: 400,372. Filing ↗machine: t134 · r5 · c7 · span 833496–833503 |
| 21 | Section 08, Scott Gottlieb | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Director Compensation”. As printed: 393,500. Filing ↗machine: t134 · r6 · c7 · span 834988–834995 |
| 22 | Section 08, James C. Smith | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Director Compensation”. As printed: 390,000. Filing ↗machine: t134 · r13 · c7 · span 846273–846280 |
| 23 | Section 08, Susan Desmond-Hellmann | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Director Compensation”. As printed: 380,522. Filing ↗machine: t134 · r4 · c7 · span 831837–831844 |
| 24 | Section 08, Cyrus Taraporevala | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Director Compensation”. As printed: 380,000. Filing ↗machine: t134 · r14 · c7 · span 848022–848029 |
| 25 | Section 08, Dan R. Littman | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Director Compensation”. As printed: 380,000. Filing ↗machine: t134 · r9 · c7 · span 840002–840009 |
| 26 | Section 08, James Quincey | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Director Compensation”. As printed: 380,000. Filing ↗machine: t134 · r12 · c7 · span 844619–844626 |
| 27 | Section 08, Susan Hockfield | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Director Compensation”. As printed: 372,000. Filing ↗machine: t134 · r8 · c7 · span 838327–838334 |
| 28 | Section 08, Mortimer J. Buckley | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Director Compensation”. As printed: 360,000. Filing ↗machine: t134 · r3 · c7 · span 830327–830334 |
| 29 | Section 08, Ronald E. Blaylock | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Director Compensation”. As printed: 360,000. Filing ↗machine: t134 · r2 · c7 · span 828657–828664 |
| 30 | Section 08, Helen H. Hobbs | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Director Compensation”. As printed: 58,448. Filing ↗machine: t134 · r7 · c1 · span 835778–835784 |
| 31 | Section 08, Albert Bourla | DEF 14A | 2026-03-12 | 0000078003-26-000033 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 32 | Section 02, Albert Bourla 2026-03-13 | Form 4 | 2026-03-16 | 0001225208-26-003710 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, James C. Smith 2026-03-27 | Form 4 | 2026-03-30 | 0001225208-26-004088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Cyrus Taraporevala 2026-03-27 | Form 4 | 2026-03-30 | 0001225208-26-004089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Joseph J. Echevarria 2026-03-27 | Form 4 | 2026-03-30 | 0001225208-26-004085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Mortimer J. Buckley 2026-03-27 | Form 4 | 2026-03-30 | 0001225208-26-004084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, James Quincey 2026-03-27 | Form 4 | 2026-03-30 | 0001225208-26-004087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Shantanu Narayen 2026-03-27 | Form 4 | 2026-03-30 | 0001225208-26-004086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Albert Bourla 2026-03-31 | Form 4 | 2026-04-01 | 0001225208-26-004140 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Albert Bourla 2026-04-14 | Form 4 | 2026-04-16 | 0001225208-26-004532 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Albert Bourla 2026-04-15 | Form 4 | 2026-04-17 | 0001225208-26-004554 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Susan Desmond-Hellmann 2026-04-23 | Form 4 | 2026-04-27 | 0001225208-26-004658 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Joseph J. Echevarria 2026-04-23 | Form 4 | 2026-04-27 | 0001225208-26-004657 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, James C. Smith 2026-04-23 | Form 4 | 2026-04-27 | 0001225208-26-004651 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Scott Gottlieb 2026-04-23 | Form 4 | 2026-04-27 | 0001225208-26-004663 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Mortimer J. Buckley 2026-04-23 | Form 4 | 2026-04-27 | 0001225208-26-004659 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, NORA JOHNSON SUZANNE M 2026-04-23 | Form 4 | 2026-04-27 | 0001225208-26-004662 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Ronald E. Blaylock 2026-04-23 | Form 4 | 2026-04-27 | 0001225208-26-004660 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Dan R. Littman 2026-04-23 | Form 4 | 2026-04-27 | 0001225208-26-004661 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Cyrus Taraporevala 2026-04-23 | Form 4 | 2026-04-27 | 0001225208-26-004650 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, James Quincey 2026-04-23 | Form 4 | 2026-04-27 | 0001225208-26-004652 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Shantanu Narayen 2026-04-23 | Form 4 | 2026-04-27 | 0001225208-26-004654 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Albert Bourla 2026-04-30 | Form 4 | 2026-05-04 | 0001225208-26-004835 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Albert Bourla 2026-05-15 | Form 4 | 2026-05-18 | 0001225208-26-005449 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Albert Bourla 2026-05-29 | Form 4 | 2026-06-01 | 0001225208-26-005687 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Jennifer B. Damico 2026-06-09 | Form 4 | 2026-06-10 | 0001225208-26-005911 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Albert Bourla 2026-06-15 | Form 4 | 2026-06-16 | 0001225208-26-006072 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Cyrus Taraporevala 2026-06-26 | Form 4 | 2026-06-30 | 0001225208-26-006255 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, James Quincey 2026-06-26 | Form 4 | 2026-06-30 | 0001225208-26-006256 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Mortimer J. Buckley 2026-06-26 | Form 4 | 2026-06-30 | 0001225208-26-006260 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Shantanu Narayen 2026-06-26 | Form 4 | 2026-06-30 | 0001225208-26-006258 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, James C. Smith 2026-06-26 | Form 4 | 2026-06-30 | 0001225208-26-006257 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Joseph J. Echevarria 2026-06-26 | Form 4 | 2026-06-30 | 0001225208-26-006259 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Albert Bourla 2026-06-30 | Form 4 | 2026-07-01 | 0001225208-26-006273 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Albert Bourla 2026-07-09 | Form 4 | 2026-07-13 | 0001225208-26-006587 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Albert Bourla 2026-07-15 | Form 4 | 2026-07-16 | 0001225208-26-006638 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 06, 2026 vote | Form 8-K | 2026-04-27 | 0000078003-26-000044 | Item 5.07 · say-on-pay result. As reported: 87.97% (votes for as printed: 3,099,249,442). Filing ↗ |
| 68 | Section 06, 2025 vote | Form 8-K | 2025-04-28 | 0000078003-25-000109 | Item 5.07 · say-on-pay result. As reported: 54.7% (votes for as printed: 1,947,064,397). Filing ↗ |
| 69 | Section 06, 2024 vote | Form 8-K | 2024-04-29 | 0000078003-24-000101 | Item 5.07 · say-on-pay result. As reported: 91.42% (votes for as printed: 3,360,637,251). Filing ↗ |
| 70 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 71 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 72 | Section 09b board cost (computed) | Computed | — | computed | Cash 2,108,970 + equity 2,460,000 + all other 105,872 = 4,674,842, summed across the director compensation table rows.machine: formula: Σ = 4,674,842 |
| 73 | Thermo Fisher Scientific Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-144585 | CEO total compensation as printed in Thermo Fisher Scientific Inc.'s own proxy. As printed: 79,923,350. Filing ↗machine: span 973487–973497 |
| 74 | International Business Machines Corporation, Section 10b CEO total | DEF 14A | 2026-03-10 | 0000051143-26-000025 | CEO total compensation as printed in International Business Machines Corporation's own proxy. As printed: 37,989,685. Filing ↗machine: r11 · c51 · span 1119293–1119303 |
| 75 | Eli Lilly and Company, Section 10b CEO total | DEF 14A | 2026-03-20 | 0000059478-26-000029 | CEO total compensation as printed in Eli Lilly and Company's own proxy. As printed: 36,698,337. Filing ↗machine: t92 · r2 · c20 · span 925013–925024 |
| 76 | Comcast Corporation, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177138 | CEO total compensation as printed in Comcast Corporation's own proxy. As printed: 35,148,413. Filing ↗machine: r4 · c25 · span 1522252–1522262 |
| 77 | Verizon Communications Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001308179-26-000210 | CEO total compensation as printed in Verizon Communications Inc.'s own proxy. As printed: 34,311,016. Filing ↗machine: t26 · r1 · c16 · span 239072–239082 |
| 78 | Johnson & Johnson, Section 10b CEO total | DEF 14A | 2026-03-11 | 0000200406-26-000063 | CEO total compensation as printed in Johnson & Johnson's own proxy. As printed: 32,758,111. Filing ↗machine: r3 · c27 · span 1621235–1621246 |
| 79 | AbbVie Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001104659-26-033387 | CEO total compensation as printed in AbbVie Inc.'s own proxy. As printed: 32,530,984. Filing ↗machine: t210 · r9 · c26 · span 1414083–1414093 |
| 80 | The Coca-Cola Company, Section 10b CEO total | DEF 14A | 2026-03-16 | 0001104659-26-028215 | CEO total compensation as printed in The Coca-Cola Company's own proxy. As printed: 31,208,165. Filing ↗machine: t286 · r11 · c26 · span 3291227–3291237 |
| 81 | Gilead Sciences, Inc., Section 10b CEO total | DEF 14A | 2026-03-20 | 0001308179-26-000106 | CEO total compensation as printed in Gilead Sciences, Inc.'s own proxy. As printed: 28,437,198. Filing ↗machine: t414 · r1 · c29 · span 989582–989592 |
| 82 | Pfizer Inc (subject), Section 10b CEO total | DEF 14A | 2026-03-12 | 0000078003-26-000033 | CEO total compensation as printed in Pfizer Inc's own proxy. As printed: 27,585,301. Filing ↗machine: t242 · r3 · c12 · span 1506825–1506835 |
| 83 | Chevron Corporation, Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-145617 | CEO total compensation as printed in Chevron Corporation's own proxy. As printed: 26,828,240. Filing ↗machine: span 1241206–1241216 |
| 84 | RTX Corporation, Section 10b CEO total | DEF 14A | 2026-03-09 | 0001308179-26-000036 | CEO total compensation as printed in RTX Corporation's own proxy. As printed: 24,846,826. Filing ↗machine: t237 · r2 · c14 · span 908955–908966 |
| 85 | Amgen Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-145588 | CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166 |
| 86 | Mondelez International, Inc., Section 10b CEO total | DEF 14A | 2026-04-03 | 0001628280-26-023640 | CEO total compensation as printed in Mondelez International, Inc.'s own proxy. As printed: 24,516,114. Filing ↗machine: r2 · c9 · span 2504218–2504228 |
| 87 | Abbott Laboratories, Section 10b CEO total | DEF 14A | 2026-03-13 | 0001308179-26-000064 | CEO total compensation as printed in Abbott Laboratories's own proxy. As printed: 24,198,660. Filing ↗machine: span 1245488–1245498 |
| 88 | PepsiCo, Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000169 | CEO total compensation as printed in PepsiCo, Inc.'s own proxy. As printed: 23,903,545. Filing ↗machine: r2 · c20 · span 826280–826290 |
| 89 | Danaher Corporation, Section 10b CEO total | DEF 14A | 2026-03-25 | 0000313616-26-000101 | CEO total compensation as printed in Danaher Corporation's own proxy. As printed: 23,795,280. Filing ↗machine: t122 · r2 · c21 · span 1070180–1070190 |
| 90 | Lockheed Martin Corporation, Section 10b CEO total | DEF 14A | 2026-03-26 | 0000936468-26-000004 | CEO total compensation as printed in Lockheed Martin Corporation's own proxy. As printed: 23,453,308. Filing ↗machine: r4 · c27 · span 1276177–1276187 |
| 91 | ConocoPhillips, Section 10b CEO total | DEF 14A | 2026-03-30 | 0001104659-26-036366 | CEO total compensation as printed in ConocoPhillips's own proxy. As printed: 23,450,085. Filing ↗machine: span 1829926–1829936 |
| 92 | Medtronic plc, Section 10b CEO total | DEF 14A | 2026-08-17 | 0001613103-26-000010 | CEO total compensation as printed in Medtronic plc's own proxy. As printed: 22,940,252. Filing ↗machine: span 988220–988230 |
| 93 | United Parcel Service, Inc., Section 10b CEO total | DEF 14A | 2026-03-19 | 0001628280-26-019856 | CEO total compensation as printed in United Parcel Service, Inc.'s own proxy. As printed: 22,878,788. Filing ↗machine: r2 · c27 · span 899122–899132 |
| 94 | The Procter & Gamble Company, Section 10b CEO total | DEF 14A | 2025-08-29 | 0001193125-25-191749 | CEO total compensation as printed in The Procter & Gamble Company's own proxy. As printed: 21,909,816. Filing ↗machine: t160 · r6 · c44 · span 892224–892234 |
| 95 | Bristol-Myers Squibb Company, Section 10b CEO total | DEF 14A | 2026-03-25 | 0000014272-26-000006 | CEO total compensation as printed in Bristol-Myers Squibb Company's own proxy. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170 |
| 96 | 3M Company, Section 10b CEO total | DEF 14A | 2026-03-25 | 0000066740-26-000151 | CEO total compensation as printed in 3M Company's own proxy. As printed: 21,005,009. Filing ↗machine: r2 · c9 · span 2797692–2797702 |
| 97 | Merck & Co., Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001193125-26-147704 | CEO total compensation as printed in Merck & Co., Inc.'s own proxy. As printed: 20,797,845. Filing ↗machine: span 1371012–1371022 |
| 98 | Honeywell International Inc., Section 10b CEO total | DEF 14A | 2026-04-10 | 0000773840-26-000029 | CEO total compensation as printed in Honeywell International Inc.'s own proxy. As printed: 20,381,435. Filing ↗machine: span 2093429–2093439 |
| 99 | Caterpillar Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001308179-26-000358 | CEO total compensation as printed in Caterpillar Inc.'s own proxy. As printed: 17,008,077. Filing ↗machine: span 855862–855872 |
| 100 | Section 10a, The Coca-Cola Company reciprocity | DEF 14A | — | 0001104659-26-028215 | The Coca-Cola Company names Pfizer Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 101 | Section 10a, Chevron Corporation reciprocity | DEF 14A | — | 0001193125-26-145617 | Chevron Corporation names Pfizer Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 102 | Section 10a, Lockheed Martin Corporation reciprocity | DEF 14A | — | 0000936468-26-000004 | Lockheed Martin Corporation's most recent proxy was read; its disclosed peer group does not include Pfizer Inc. Filing ↗ |
| 103 | Section 10a, Mondelez International, Inc. reciprocity | DEF 14A | — | 0001628280-26-023640 | Mondelez International, Inc.'s most recent proxy was read; its disclosed peer group does not include Pfizer Inc. Filing ↗ |
| 104 | Section 10a, United Parcel Service, Inc. reciprocity | DEF 14A | — | 0001628280-26-019856 | United Parcel Service, Inc.'s most recent proxy was read; its disclosed peer group does not include Pfizer Inc. Filing ↗ |
| 105 | Section 10a, Gilead Sciences, Inc. reciprocity | DEF 14A | — | 0001308179-26-000106 | Gilead Sciences, Inc. names Pfizer Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 106 | Section 10a, 3M Company reciprocity | DEF 14A | — | 0000066740-26-000151 | 3M Company's most recent proxy was read; its disclosed peer group does not include Pfizer Inc. Filing ↗ |
| 107 | Section 10a, Merck & Co., Inc. reciprocity | DEF 14A | — | 0001193125-26-147704 | Merck & Co., Inc. names Pfizer Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 108 | Section 10a, Danaher Corporation reciprocity | DEF 14A | — | 0000313616-26-000101 | Danaher Corporation's most recent proxy was read; its disclosed peer group does not include Pfizer Inc. Filing ↗ |
| 109 | Section 10a, Honeywell International Inc. reciprocity | DEF 14A | — | 0000773840-26-000029 | Honeywell International Inc.'s most recent proxy was read; its disclosed peer group does not include Pfizer Inc. Filing ↗ |
| 110 | Section 10a, Amgen Inc. reciprocity | DEF 14A | — | 0001193125-26-145588 | Amgen Inc. names Pfizer Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 111 | Section 10a, Bristol-Myers Squibb Company reciprocity | DEF 14A | — | 0000014272-26-000006 | Bristol-Myers Squibb Company names Pfizer Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 112 | Section 10a, Caterpillar Inc. reciprocity | DEF 14A | — | 0001308179-26-000358 | Caterpillar Inc.'s most recent proxy was read; its disclosed peer group does not include Pfizer Inc. Filing ↗ |
| 113 | Section 10a, Comcast Corporation reciprocity | DEF 14A | — | 0001193125-26-177138 | Comcast Corporation's most recent proxy was read; its disclosed peer group does not include Pfizer Inc. Filing ↗ |
| 114 | Section 10a, Johnson & Johnson reciprocity | DEF 14A | — | 0000200406-26-000063 | Johnson & Johnson names Pfizer Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 115 | Section 10a, The Procter & Gamble Company reciprocity | DEF 14A | — | 0001193125-25-191749 | The Procter & Gamble Company names Pfizer Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 116 | Section 10a, Eli Lilly and Company reciprocity | DEF 14A | — | 0000059478-26-000029 | Eli Lilly and Company names Pfizer Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 117 | Section 10a, International Business Machines Corporation reciprocity | DEF 14A | — | 0000051143-26-000025 | International Business Machines Corporation's most recent proxy was read; its disclosed peer group does not include Pfizer Inc. Filing ↗ |
| 118 | Section 10a, Verizon Communications Inc. reciprocity | DEF 14A | — | 0001308179-26-000210 | Verizon Communications Inc.'s most recent proxy was read; its disclosed peer group does not include Pfizer Inc. Filing ↗ |
| 119 | Section 10a, ConocoPhillips reciprocity | DEF 14A | — | 0001104659-26-036366 | ConocoPhillips's most recent proxy was read; its disclosed peer group does not include Pfizer Inc. Filing ↗ |
| 120 | Section 10a, AbbVie Inc. reciprocity | DEF 14A | — | 0001104659-26-033387 | AbbVie Inc. names Pfizer Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 121 | Section 10a, RTX Corporation reciprocity | DEF 14A | — | 0001308179-26-000036 | RTX Corporation's most recent proxy was read; its disclosed peer group does not include Pfizer Inc. Filing ↗ |